Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
DPD deficiency
DPD phenotype
DPYD genotype
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
09
11
2022
revised:
21
12
2022
accepted:
24
12
2022
pubmed:
16
2
2023
medline:
8
3
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
In 2020, the European Medicines Agency recommended testing patients for dihydropyrimidine dehydrogenase (DPD) deficiency before systemic treatment with fluoropyrimidines (FP). DPD activity testing identifies patients at elevated risk of severe FP-related toxicity (FP-TOX). The two most used methods for DPD testing are DPYD genotyping and DPD phenotyping (plasma uracil concentration). The primary objective of this study was to compare the overall frequency of overall grade ≥3 FP-TOX before and after the implementation of DPYD genotyping. Two hundred thirty Danish, primarily gastrointestinal cancer patients, were DPYD-genotyped before their first dose of FP, and blood was sampled for post hoc assessment of P-uracil. The initial dose was reduced for variant carriers. Grade ≥3 FP-TOX was registered after the first three treatment cycles of FP. The frequency of toxicity was compared to a historical cohort of 492 patients with post hoc determined DPYD genotype from a biobank. The frequency of overall grade ≥3 FP-TOX was 27% in the DPYD genotype-guided group compared to 24% in the historical cohort. In DPYD variant carriers, DPYD genotyping reduced the frequency of FP-related hospitalization from 19% to 0%. In the control group, 4.8% of DPYD variant carriers died due to FP-TOX compared to 0% in the group receiving DPYD genotype-guided dosing of FP. In the intervention group, wild-type patients with uracil ≥16 ng/ml had a higher frequency of FP-TOX than wild-type patients with uracil <16 ng/ml (55% versus 28%). We found no population-level benefit of DPYD genotyping when comparing the risk of grade ≥3 FP-TOX before and after clinical implementation. We observed no deaths or FP-related hospitalizations in patients whose FP treatment was guided by a variant DPYD genotype. The use of DPD phenotyping may add valuable information in DPYD wild-type patients.
Sections du résumé
BACKGROUND
In 2020, the European Medicines Agency recommended testing patients for dihydropyrimidine dehydrogenase (DPD) deficiency before systemic treatment with fluoropyrimidines (FP). DPD activity testing identifies patients at elevated risk of severe FP-related toxicity (FP-TOX). The two most used methods for DPD testing are DPYD genotyping and DPD phenotyping (plasma uracil concentration). The primary objective of this study was to compare the overall frequency of overall grade ≥3 FP-TOX before and after the implementation of DPYD genotyping.
PATIENTS AND METHODS
Two hundred thirty Danish, primarily gastrointestinal cancer patients, were DPYD-genotyped before their first dose of FP, and blood was sampled for post hoc assessment of P-uracil. The initial dose was reduced for variant carriers. Grade ≥3 FP-TOX was registered after the first three treatment cycles of FP. The frequency of toxicity was compared to a historical cohort of 492 patients with post hoc determined DPYD genotype from a biobank.
RESULTS
The frequency of overall grade ≥3 FP-TOX was 27% in the DPYD genotype-guided group compared to 24% in the historical cohort. In DPYD variant carriers, DPYD genotyping reduced the frequency of FP-related hospitalization from 19% to 0%. In the control group, 4.8% of DPYD variant carriers died due to FP-TOX compared to 0% in the group receiving DPYD genotype-guided dosing of FP. In the intervention group, wild-type patients with uracil ≥16 ng/ml had a higher frequency of FP-TOX than wild-type patients with uracil <16 ng/ml (55% versus 28%).
CONCLUSIONS
We found no population-level benefit of DPYD genotyping when comparing the risk of grade ≥3 FP-TOX before and after clinical implementation. We observed no deaths or FP-related hospitalizations in patients whose FP treatment was guided by a variant DPYD genotype. The use of DPD phenotyping may add valuable information in DPYD wild-type patients.
Identifiants
pubmed: 36791638
pii: S2059-7029(23)00002-9
doi: 10.1016/j.esmoop.2023.100782
pmc: PMC10024141
pii:
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Capecitabine
6804DJ8Z9U
Dihydrouracil Dehydrogenase (NADP)
EC 1.3.1.2
Uracil
56HH86ZVCT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100782Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have declared no conflicts of interest.
Références
Br J Clin Pharmacol. 2016 Sep;82(3):706-16
pubmed: 27161955
Swiss Med Wkly. 2020 Nov 24;150:w20375
pubmed: 33232506
J Clin Oncol. 2001 Apr 15;19(8):2282-92
pubmed: 11304782
JAMA Oncol. 2016 May 01;2(5):655-662
pubmed: 26794347
Oncologist. 2021 Dec;26(12):1008-1016
pubmed: 34506675
Semin Oncol. 2017 Feb;44(1):13-23
pubmed: 28395758
Br J Cancer. 2020 Sep;123(5):811-818
pubmed: 32595208
Ugeskr Laeger. 2010 May 10;172(19):1446-50
pubmed: 20470655
Int J Cancer. 2015 Feb 1;136(3):730-9
pubmed: 24923815
Acta Oncol. 2022 Nov;61(11):1400-1405
pubmed: 36256873
Br J Clin Pharmacol. 2018 Dec;84(12):2761-2769
pubmed: 30047584
Lancet Oncol. 2018 Nov;19(11):1459-1467
pubmed: 30348537
Clin Pharmacol Ther. 2018 Feb;103(2):210-216
pubmed: 29152729
Cancer Chemother Pharmacol. 2021 Dec;88(6):1049-1053
pubmed: 34515833
J Pharm Biomed Anal. 2016 Jul 15;126:75-82
pubmed: 27179185
J Oncol Pharm Pract. 2023 Jan;29(1):5-13
pubmed: 34797200
Clin Pharmacol Ther. 2022 Jul;112(1):62-68
pubmed: 35397172
Eur J Hum Genet. 2020 Apr;28(4):508-517
pubmed: 31745289
N Engl J Med. 2005 Jun 30;352(26):2696-704
pubmed: 15987918
Pharmgenomics Pers Med. 2021 Dec 09;14:1603-1617
pubmed: 34916829
Clin Transl Sci. 2021 Jul;14(4):1338-1348
pubmed: 33620159
Ther Adv Med Oncol. 2012 Jul;4(4):167-72
pubmed: 22754590
Basic Clin Pharmacol Toxicol. 2022 Nov;131(5):325-346
pubmed: 35997509